After averting the spin-off for years, GSK has finally made up its mind about letting go of the consumer health business. It has announced a JV of its consumer health business with Pfizer’s, which had repeatedly failed in securing a buyer for its consumer health business for quarters. The deal, expected to close in H2 19, is part of the bigger plan to offload eventually the business completely. Within three years of closing the transaction, GSK will look at a separate listing of the JV
19 Dec 2018
The beginning of an end
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
The beginning of an end
GSK plc (GSK:LON) | 1,640 73.8 0.3% | Mkt Cap: 67,986m
- Published:
19 Dec 2018 -
Author:
Kamla Singh -
Pages:
2
After averting the spin-off for years, GSK has finally made up its mind about letting go of the consumer health business. It has announced a JV of its consumer health business with Pfizer’s, which had repeatedly failed in securing a buyer for its consumer health business for quarters. The deal, expected to close in H2 19, is part of the bigger plan to offload eventually the business completely. Within three years of closing the transaction, GSK will look at a separate listing of the JV